search
Back to results

The Role of Melatonin in the Regulation of Blood Coagulation (COME)

Primary Purpose

Spinal Cord Injured, Tetraplegia

Status
Completed
Phase
Phase 1
Locations
Norway
Study Type
Interventional
Intervention
Melatonin ("Circadin")
Sponsored by
University of Oslo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Spinal Cord Injured, Tetraplegia focused on measuring Circadian variation, hemostasis, melatonin, tetraplegia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Intervention group:

  • A diagnosis of tetraplegia for at least 2 years, and otherwise healthy.
  • Must not use drugs permanently (except anti-spasmolytics).
  • Must be able to swallow tablets.
  • Must give written consent to participate.

Control group:

  • Must be healthy.
  • Must not use drugs permanently.
  • Must give written consent to participate.

Exclusion Criteria:

Both groups:

  • Those with acute or chronic co-morbidity.
  • Unable to cooperate.
  • Not provided written consent to participate.

Sites / Locations

  • Sunnaas Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Sleep only

Melatonin

Arm Description

Placebo given at night to tetraplegic individuals before going to sleep,

Melatonin given at night to tetraplegic individuals before going to sleep.

Outcomes

Primary Outcome Measures

Circadian variation of hemostatic factors

Secondary Outcome Measures

Full Information

First Posted
November 30, 2012
Last Updated
October 13, 2017
Sponsor
University of Oslo
Collaborators
Sunnaas Hospital, Oslo University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01741389
Brief Title
The Role of Melatonin in the Regulation of Blood Coagulation
Acronym
COME
Official Title
The Role of Melatonin in the Regulation of Blood Coagulation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Oslo
Collaborators
Sunnaas Hospital, Oslo University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main aim is to examine the influence of daylight and melatonin on the temporal variations of hemostatic factors with key roles in the hemostatic process and its regulation. Particular emphasis will be on exploring the role of melatonin in hemostasis by comparing subjects with tetraplegia with able-bodied control subjects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injured, Tetraplegia
Keywords
Circadian variation, hemostasis, melatonin, tetraplegia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sleep only
Arm Type
Placebo Comparator
Arm Description
Placebo given at night to tetraplegic individuals before going to sleep,
Arm Title
Melatonin
Arm Type
Active Comparator
Arm Description
Melatonin given at night to tetraplegic individuals before going to sleep.
Intervention Type
Drug
Intervention Name(s)
Melatonin ("Circadin")
Primary Outcome Measure Information:
Title
Circadian variation of hemostatic factors
Time Frame
24 hours

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Intervention group: A diagnosis of tetraplegia for at least 2 years, and otherwise healthy. Must not use drugs permanently (except anti-spasmolytics). Must be able to swallow tablets. Must give written consent to participate. Control group: Must be healthy. Must not use drugs permanently. Must give written consent to participate. Exclusion Criteria: Both groups: Those with acute or chronic co-morbidity. Unable to cooperate. Not provided written consent to participate.
Facility Information:
Facility Name
Sunnaas Hospital
City
Nesodden
ZIP/Postal Code
1450
Country
Norway

12. IPD Sharing Statement

Citations:
PubMed Identifier
16879232
Citation
Dahm A, Osterud B, Hjeltnes N, Sandset PM, Iversen PO. Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation? J Thromb Haemost. 2006 Aug;4(8):1840-2. doi: 10.1111/j.1538-7836.2006.02048.x. No abstract available.
Results Reference
background
PubMed Identifier
21297449
Citation
Kostovski E, Dahm AE, Iversen N, Hjeltnes N, Osterud B, Sandset PM, Iversen PO. Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul Fibrinolysis. 2011 Jun;22(4):254-9. doi: 10.1097/MBC.0b013e3283442ce2.
Results Reference
background
PubMed Identifier
16139333
Citation
Dahm AE, Iversen PO, Hjeltnes N, Sandset PM. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. Thromb Res. 2006;118(2):281-7. doi: 10.1016/j.thromres.2005.07.021. Epub 2005 Aug 31.
Results Reference
background

Learn more about this trial

The Role of Melatonin in the Regulation of Blood Coagulation

We'll reach out to this number within 24 hrs